Improving patient outcomes through collaboration

The return on R&D investments in the UK is at its lowest rate in nine years, despite Britain’s global presence in science, technology and health. Pharmaceutical attrition rates continue to rise, and the UK biotech landscape remains fragmented. Medicines Discovery Catapult (MDC) aims to connect the UK R&D community more effectively by putting the patient at the heart of the drug discovery process. As part of our collaboration with the MDC, REPROCELL have pledged to provide custom drug discovery assays using live human tissues.

Continue reading 

3D epithelial barrier assays in vitro: How to get the best balance between practicability and physiological relevance

Barrier assays are an important tool for in vitro drug development and drug safety testing, e.g. assessing the absorption of a drug candidate through the intestinal wall or the corrosion of chemical compounds on skin.

Continue reading 

Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow

REPROCELL Europe Ltd was pleased to receive a visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017.

Continue reading 

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.

Continue reading 

Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)

This following video is from Nicola Sturgeon, First Minister of Scotland's YouTube channel:

Continue reading 

Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow

New headquarters strengthen drug discovery services and translational research, and generate new employment opportunities in Scotland. Press release 10th August 2017.

Continue reading 

REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research

REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer using techniques such as 3D models, PDX systems and precision-cut tumour slices. Chaired by Professor Gareth Thomas of the University of Southampton, presentations were delivered from, among others, Professor Will Shu and Dr Nick Lesley, who described developments in 3D bioprinting of tumours, and Dr Phil Quinlan of the UKCRC Tissue Directory.

Continue reading 

Prof Stefan Przyborski to chair the SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb)

The SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb) will be chaired by REPROCELL Europe’s chief scientific officer (CSO), Professor Stefan Przyborski. He will also be giving the first lecture in the conference.

Continue reading 

REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex

REPROCELL Europe has won the Corporate Vision Technology Innovation Award 2016 for Alvetex technology for 3D cell culture.

Continue reading 

Prof Stefan Przyborski speaking at BBS 2016 Biennial Meeting

ReproCELL Europe Ltd’s Chief Scientific Officer Prof Stefan Przyborski is giving a public lecture on “Scaffold Cell Culture Technology for Generation of In Vivo-like Tissue Models” at the British Biophysical Society 2016 Biennial Meeting 6th-8th July, University of Liverpool, Liverpool, UK.

Continue reading